GlassScriptPhysician profile
Jonathan Torres Luna
NPI 1225396302
$2,831.68
in general payments reported to CMS, 2019-2025
17 companies · $624 in 2025
The $624 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $374 · 2021: $318 · 2022: $185 · 2023: $388 · 2024: $630 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,642.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $654.05 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $622.64 | 2019-2025 | Ofev, Jascayd |
| Glaxosmithkline, LLC. | $583.33 | 2019-2025 | Nucala |
| Grifols USA, LLC | $232.87 | 2019-2024 | Prolastin-C Liquid |
| Amgen INC. | $121.33 | 2023-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $108.64 | 2019-2025 | Capvaxive, Winrevair |
| Mallinckrodt Hospital Products INC. | $101.60 | 2024 | Acthar |
| Genzyme Corporation | $97.10 | 2019-2025 | |
| Mylan Specialty L.P. | $51.45 | 2021-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $50.00 | 2023-2024 | Glassia, Hyqvia |
| Harmony Biosciences LLC | $50.00 | 2025 | |
| Jazz Pharmaceuticals INC. | $42.16 | 2021-2024 | |
| Abbvie INC. | $29.95 | 2023 | Avycaz |
| Eli Lilly Export S.A. Puerto Rico Branch | $25.00 | 2025 | Zepbound |
| Novartis Pharmaceuticals Corporation | $24.41 | 2019-2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $23.93 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Torres Luna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.